title: Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy.
abstract: The influence of nicotinamide formulation on absorption characteristics and incidence of adverse side-effects has been studied in normal volunteers and in patients undergoing radiotherapy. Escalating single or repeated oral doses of nicotinamide were administered in tablet or liquid form under fasting or non-fasting conditions. Drug absorption was slowed both by the presence of food in the stomach and by the administration of nicotinamide in tablet form compared with when it was dissolved in orange juice. Peak concentrations were generally slightly higher following the liquid preparation, but the incidence of adverse side-effects (chiefly nausea) was increased. A single dose of 9 g (88-97 mg/kg) nicotinamide in tablet form was well tolerated in two fasting normal volunteers, and in patients, doses of up to 133 mg/kg as tablets were tolerated twice/week for three weeks. Daily administration of 80 mg/kg nicotinamide was tolerated when given as tablets, but not in a liquid formulation. Neither the peak concentration nor the area under the concentration/time curve (AUC) of nicotinamide, nor the main metabolites of nicotinamide appeared to correlate with the incidence of toxicity.
authors.affiliation: Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, England.
authors.forename: M R
authors.initials: MR
authors.lastname: Stratford
authors.forename: M F
authors.initials: MF
authors.lastname: Dennis
authors.forename: P J
authors.initials: PJ
authors.lastname: Hoskin
authors.forename: M I
authors.initials: MI
authors.lastname: Saunders
authors.forename: R J
authors.initials: RJ
authors.lastname: Hodgkiss
authors.forename: A
authors.initials: A
authors.lastname: Rojas
mesh_terms: D000284:Administration, Oral; D005260:Female; D006207:Half-Life; D006801:Humans; D015994:Incidence; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000532:radiotherapy*; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D010166:Palliative Care; D012016:Reference Values; D013997:Time Factors
chemical_list: D009536:Niacinamide